Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolpidem PK in Men With Prostate Cancer Undergoing ADT vs Healthy Females
NCT03436745Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2019
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of zolpidem sublingual tablet in Insomnia (2 arms), sponsored by National Cancer Institute. Primary endpoint: Change in Area Under the Plasma Concentration 0-8Hour Curve. Started Jan 2019; status: terminated.
02
Drugs
zolpidem sublingual tablet
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03436745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436745.